D a t a s o u r c e s
Studies were identified by searching MED-LINE (1966 to 2000 , CINAHL (1982 CINAHL ( to 2000 , Cochrane Airways Group's registry of randomized controlled trials (RCTs) in COPD (up to 2000) , and lists of conference abstracts. Bibliographies of relevant articles were reviewed, and experts in the field were contacted for unpublished studies.
S t u d y s e l e c t i o n
Studies published in any language were selected if they were RCTs comparing respiratory rehabilitation (any in-patient, out-patient, or home-based rehabilitation program that lasted ≥ 4 wk and included exercise therapy with or without any form of education or psychological support) with conventional community care, and > 90% of patients had a clinical diagnosis of COPD with either a best recorded FEV 1 /forced vital capacity ratio of individual patients < 0.7 or best recorded FEV 1 of individual patients < 70% of the predicted FEV 1 value. D a t a e x t r a c t i o n 2 reviewers extracted data on patient characteristics; the setting, components, and duration of the rehabilitation program; and outcomes. Outcomes included HRQL (Chronic Respiratory Disease Questionnaire) and maximal (incremental cycle ergometer test) or functional (6-minute walk test) exercise capacity.
M a i n r e s u l t s 23 RCTs met the selection criteria. Improvement in all outcomes was greater in the rehabilitation group than in the conventional-care group (Table) . For each of the 4 main features of HRQL (dyspnea, fatigue, emotional function, and mastery), the treatment effect was larger than the minimal clinically important difference of 0.5 on the 7-point scale (Table) .
C o n c l u s i o n
In patients with chronic obstructive pulmonary disease, respiratory rehabilitation is more effective than conventional community care for improving health-related quality of life. C o m m e n t a r y COPD has emerged as a major health problem throughout the world and is likely to increase over the next decade. Not smoking remains the most important aspect of both treatment and prevention. Nonetheless, a need exists to manage the chronic dyspnea and limitation to functional capacity that persons with COPD have on a daily basis. The review by Lacasse and colleagues describes the role of respiratory rehabilitation in addressing these issues. A high-quality, systematic review of RCTs was done, and the results identify important benefits of respiratory rehabilitation on dyspnea, HRQL, and exercise capacity. The review takes a "global approach" to examining respiratory rehabilitation, where several types of programs are combined in a single analysis. This approach obviously has advantages and disadvantages. One of the benefits is that an overall conclusion can be reached concerning the benefits of respiratory rehabilitation. A limitation is that the effectiveness of individual components cannot be ascertained; however, other studies have examined this issue and are referenced in the discussion of the review.
The strength of the effect should be enough to convince physicians and patients about the benefits of respiratory rehabilitation. However, access to these programs remains a problem, and this review probably won't convince health administrators to fund new programs. A health economic analysis is required for such funding to occur, together with strong advocacy.
In providing clear results of a strong effect of respiratory rehabilitation in COPD, Lacasse and colleagues shift the focus to how these effects can be achieved in the general community. It amazes me that as physicians we continue to prescribe expensive pharmacotherapy that is considerably less effective than respiratory rehabilitation for a disease that by definition is resistant to drug therapy, yet we can't access respiratory rehabilitation. Perhaps every drug script should be accompanied by a letter to our local health administrator seeking improved access to respiratory rehabilitation.
Peter G. Gibson, MD John Hunter Hospital Newcastle, New South Wales, Australia 
